Journal
MEDICAL MYCOLOGY
Volume 46, Issue 3, Pages 259-263Publisher
INFORMA HEALTHCARE
DOI: 10.1080/13693780701558969
Keywords
chronic myeloid leukemia (CML); Candida krusei; Candida glabrata; imatinib; TLR
Categories
Ask authors/readers for more resources
In this report we describe a patient suffering from chronic myeloid leukemia (CML), who was treated for 4.5 years with imatinib and developed pneumonia caused by two Candida species, i.e., C. krusei and C. glabrata. The patient was in complete hematologic remission and molecular analyses did not display the presence of TLR2-R752Q, TLR4-D299G and TLR4-T399I polymorphisms that may predispose individuals to fungal infections. This case report indicates that in some patients, as previously observed, the long-term administration of targeted therapy might affect immunity and predispose patients to opportunistic and life-threatening fungal infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available